Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
SPONSORED CONTENTGive your patients FAST diarrhea reliefProbiotics or nutrition? Prioritize Hill's Prescription Diet GIB nutrition clinically shown to resolve diarrhea in as little as 24 hours. + Learn More